Open access
Lecanemab in symptomatic PSEN1 p.Met233Val early‐onset Alzheimer's disease: Neuroimaging safety, regional amyloid‐PET dynamics, and longitudinal plasma biomarkers
Min-Young Noh
Wonjae Sung
Hyunkee Kim
Bugyeong Son
Young-Eun Kim
Yun Y. Choi
David M. Holtzman
Seung Hyun Kim
Medicine
Abstract
The presenilin 1 (PSEN1) p.Met233Val variant is a Dominantly Inherited Alzheimer Network–Trials Unit (DIAN‐TU)–eligible autosomal‐dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable.